title: Exercise-induced prostacyclin release positively correlates with VO(2max) in young healthy men.
abstract: In this study we have evaluated the effect of maximal incremental cycling exercise (IE) on the systemic release of prostacyclin (PGI(2)), assessed as plasma 6-keto-PGF(1alpha) concentration in young healthy men. Eleven physically active - untrained men (mean +/- S.D.) aged 22.7 +/- 2.1 years; body mass 76.3 +/- 9.1 kg; BMI 23.30 +/- 2.18 kg . m(-2); maximal oxygen uptake (VO(2max)) 46.5 +/- 3.9 ml . kg(-1) . min(-1), performed an IE test until exhaustion. Plasma concentrations of 6-keto-PGF(1alpha), lactate, and cytokines were measured in venous blood samples taken prior to the exercise and at the exhaustion. The net exercise-induced increase in 6-keto-PGF(1alpha) concentration, expressed as the difference between the end-exercise minus pre-exercise concentration positively correlated with VO(2max) (r=0.78, p=0.004) as well as with the net VO(2) increase at exhaustion (r=0.81, p=0.003), but not with other respiratory, cardiac, metabolic or inflammatory parameters of the exercise (minute ventilation, heart rate, plasma lactate, IL-6 or TNF-alpha concentrations). The exercise-induced increase in 6-keto-PGF(1alpha) concentration?? was significantly higher (p=0.008) in a group of subjects (n=5) with the highest VO(2max) when compared to the group of subjects with the lowest VO(2max), in which no increase in 6-keto-PGF(1alpha) concentration was found. In conclusion, we demonstrated, to our knowledge for the first time, that exercise-induced release of PGI(2) in young healthy men correlates with VO(2max), suggesting that vascular capacity to release PGI(2) in response to physical exercise represents an important factor characterizing exercise tolerance. Moreover, we postulate that the impairment of exercise-induced release of PGI(2) leads to the increased cardiovascular hazard of vigorous exercise.
authors.affiliation: Department of Physiology and Biochemistry, University School of Physical Education, Kraków, Poland. Jerzy.Zoladz@awf.krakow.pl
authors.forename: J A
authors.initials: JA
authors.lastname: Zoladz
authors.forename: J
authors.initials: J
authors.lastname: Majerczak
authors.forename: K
authors.initials: K
authors.lastname: Duda
authors.forename: S
authors.initials: S
authors.lastname: Chłopicki
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D011464:Epoprostenol / Q000097:blood*; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D019344:Lactic Acid / Q000097:blood; D008297:Male; D010101:Oxygen Consumption / Q000502:physiology*; D012123:Pulmonary Ventilation / Q000502:physiology; D012146:Rest / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D055815:Young Adult
chemical_list: D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D019344:Lactic Acid; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol